Jefferies initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $26 price target Crescent is a preclinical-stage oncology company with CR-001 as its lead asset, the analyst tells investors in a research note. Jefferies believes in the PD-(L)1xVEGF class and sees an “intriguing” risk/reward at current share levels.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO: